Hematology/Oncology Department
Research Studies Open for Enrollment
|
UCSF Benioff Children's Hospital Oakland Hematology/Oncology Department Research Studies Open for Enrollment |
Date: 11/15/2019 |
|---|
| Title | ID/Protocol | NCT/Phase | Sponsor | P.I. | Contact |
| ONCOLOGY | |||||
|---|---|---|---|---|---|
| Pediatric Tissue Bank at the Children's Hospital & Research Center Oakland | ONC Tissue Bank | N/A | Jon Rowland, MD | ||
| The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT) | ACCL1633 | N/A Phase 3 | Children's Oncology Group (COG) | Carla Golden, MD | Christine Ho (510-428-3885 x 2609) |
| Solid Tumors | |||||
| Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) | AHEP1531 | N/A Phase 3 | Children's Oncology Group (COG) | Carla Golden, MD | Christine Ho (510-428-3885 x 2609) |
| ONCOLOGY: EARLY PHASE | |||||
| A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard Immunotherapy with or w/o DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma | NMTRC012 | NCT02559778 Phase 2 | Beat Childhood Cancer (BCC) | Anu Agrawal, MD | Jennifer Michlitsch, MD |
| Leukemia, Lymphoma | |||||
| Pilot Study of Mitoxantrone in combination with Clofarabine in Children, Adolescents and Young Adults with Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma | MITCL | NCT01842672 Phase 1/2a | New York Medical College | Jennifer Michlitsch, MD | Jennifer Michlitsch, MD |
| Lymphoma | |||||
| Risk adapted, response based trial of nivolumab and brentuximab vedotin followed by brentuximab vedotin and bendamustine for pediatric and young adults with relapsed or refractory CD30 positive classic Hodgkin lymphoma | AHOD1721 | NCT02927769 Phase 2 | Children's Oncology Group | Carla Golden, MD | Christine Ho (510-428-3885 x 2609) |
| Lymphoma, Solid Tumors | |||||
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations | APEC1621B | NCT03210714 Phase 2 | Children's Oncology Group | Carla Golden, MD | Christine Ho (510-428-3885 x 2609) |
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusions | APEC1621A | NCT03213704 Phase 2 | Children's Oncology Group | Carla Golden, MD | Christine Ho (510-428-3885 x 2609) |
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LY3023414 in Solid Tumors | APEC1621D | NCT03155620 Phase 2 | Children's Oncology Group | Carla Golden, MD | Christine Ho (510-428-3885 x 2609) |
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes | APEC1621H | NCT03233204 Phase 2 | Children's Oncology Group | Carla Golden, MD | Christine Ho (510-428-3885 x 2609) |
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of tazemetostat for patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex | APEC1621C | NCT03213665 Phase 2 | Children's Oncology Group | Carla Golden, MD | Christine Ho (510-428-3885 x 2609) |
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations | APEC1621F | NCT03213652 Phase 2 | Children's Oncology Group | Carla Golden, MD | Christine Ho (510-428-3885 x 2609) |
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations | APEC1621G | NCT03220035 Phase 2 | Children's Oncology Group | Carla Golden, MD | Christine Ho (510-428-3885 x 2609) |
| Solid Tumors | |||||
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes | APEC1621I | N/A Phase 2 | Children's Oncology Group | Carla Golden, MD | Christine Ho (510-428-3885 x 2609) |
| Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine | NMTRC-014-DFMO | NCT02679144 Phase 2 | Beat Childhood Cancer (BCC) | Anu Agrawal, MD | Anu Agrawal, MD (510-428-3885 x3539) |
| Pazopanib in Combination with Irinotecan and Temozolomide for Children and Young Adults with Relapsed or Refractory Sarcoma | PAZIT | NCT03139331 Phase 1 | University of California, San Francisco | Jennifer Michlitsch, MD | Jennifer Michlitsch, MD |
| Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors | ADVL1622 | NCT02867592 Phase 2 | Children's Oncology Group | Carla Golden, MD | Christine Ho (510-428-3885 x 2609) |
| Two-Part Study of TB-403 in Pediatric Subjects with Relapsed or Refractory Medulloblastoma, Neuroblastoma, Ewing Sarcoma or Alveolar Rhabdomyosarcoma | TB-403 | NCT02748135 Phase 1/2a | Beat Childhood Cancer (BCC) and Oncurious NV | Jennifer Michlitsch, MD | Jennifer Michlitsch, MD (510-428-3885 x3264) |
| STEM CELL TRANSPLANTATION AND CELLULAR THERAPY | |||||
| Oncology | |||||
| Role of KIR-favorably Mismatched Haploidentical Transplantation and KIR-polymorphisms in Determining Outcomes of Children with ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation | ONC1401 | NCT02646839 Phase 1/2 | Pediatric Blood and Marrow Transplatn Consortium | Nahal Rose Lalefar, MD | Marci Moriarty, RN (510-428-3385 x5396) |
| Oncology: Early Phase, Leukemia | |||||
| Pediatric and Young Adult Leukemia Adoptive Therapy. A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia | PLAT-02 | NCT02028455 Phase 1/2 | Seattle Children's Hospital | Anu Agrawal, MD | Marci Moriarty, RN (510-428-3385 x5396) |